Titre : Mitogen-Activated Protein Kinase 3

Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Meta-Analysis as Topic
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes", "headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-02-18", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Extracellular Signal-Regulated MAP Kinases", "url": "https://questionsmedicales.fr/mesh/D048049", "about": { "@type": "MedicalCondition", "name": "Extracellular Signal-Regulated MAP Kinases", "code": { "@type": "MedicalCode", "code": "D048049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.567.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitogen-Activated Protein Kinase 3", "alternateName": "Mitogen-Activated Protein Kinase 3", "code": { "@type": "MedicalCode", "code": "D048052", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Juan Wang", "url": "https://questionsmedicales.fr/author/Juan%20Wang", "affiliation": { "@type": "Organization", "name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea." } }, { "@type": "Person", "name": "Mohammad Shafiq", "url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Kumaravelu Jagavelu", "url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu", "affiliation": { "@type": "Organization", "name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Neeraj Kumar Verma", "url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } }, { "@type": "Person", "name": "Jimut Kanti Ghosh", "url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh", "affiliation": { "@type": "Organization", "name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Medical Management of Headache and Facial Pain in CRS: A Systematic Review and Meta-Analysis.", "datePublished": "2024-05-10", "url": "https://questionsmedicales.fr/article/38727514", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/lary.31502" } }, { "@type": "ScholarlyArticle", "name": "The effect of social anxiety on threat acquisition and extinction: a systematic review and meta-analysis.", "datePublished": "2024-05-09", "url": "https://questionsmedicales.fr/article/38737738", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7717/peerj.17262" } }, { "@type": "ScholarlyArticle", "name": "The Effects of Osteopathic Manipulative Treatment (OMT) on Postoperative Length of Stay: A Meta-Analysis.", "datePublished": "2024-05-09", "url": "https://questionsmedicales.fr/article/38854331", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.7759/cureus.59983" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of the impact of prospective payment systems on cholecystectomy: A systematic review and meta-analysis.", "datePublished": "2024-05-07", "url": "https://questionsmedicales.fr/article/38710538", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.14701/ahbps.24-038" } }, { "@type": "ScholarlyArticle", "name": "Incidence and Association of Uveitis with COVID-19 Vaccination: A Systematic Review and Meta-Analysis.", "datePublished": "2024-05-06", "url": "https://questionsmedicales.fr/article/38709174", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/09286586.2024.2343714" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Mitogen-Activated Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D020928" }, { "@type": "ListItem", "position": 7, "name": "Extracellular Signal-Regulated MAP Kinases", "item": "https://questionsmedicales.fr/mesh/D048049" }, { "@type": "ListItem", "position": 8, "name": "Mitogen-Activated Protein Kinase 3", "item": "https://questionsmedicales.fr/mesh/D048052" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3", "description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Meta-Analysis+as+Topic&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitogen-Activated Protein Kinase 3", "description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Meta-Analysis+as+Topic&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitogen-Activated Protein Kinase 3", "description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Meta-Analysis+as+Topic&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitogen-Activated Protein Kinase 3", "description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Meta-Analysis+as+Topic&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitogen-Activated Protein Kinase 3", "description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Meta-Analysis+as+Topic&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3", "description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?", "url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Meta-Analysis+as+Topic&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction de MAPK3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer MAPK3 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de phosphorylation et les analyses protéomiques sont courants." } }, { "@type": "Question", "name": "Y a-t-il des biomarqueurs associés à MAPK3 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3." } }, { "@type": "Question", "name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est liée à des cancers et des maladies inflammatoires." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une activation excessive peut entraîner une inflammation et des douleurs." } }, { "@type": "Question", "name": "MAPK3 affecte-t-elle le système immunitaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à MAPK3 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3." } }, { "@type": "Question", "name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose." } }, { "@type": "Question", "name": "Comment prévenir les dysfonctionnements de MAPK3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé." } }, { "@type": "Question", "name": "Y a-t-il des habitudes à éviter pour MAPK3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé." } }, { "@type": "Question", "name": "Le stress peut-il affecter MAPK3 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la signalisation de MAPK3." } }, { "@type": "Question", "name": "Des exercices spécifiques aident-ils MAPK3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3." } }, { "@type": "Question", "name": "La gestion du poids influence-t-elle MAPK3 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quels traitements ciblent MAPK3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers." } }, { "@type": "Question", "name": "La thérapie génique peut-elle corriger MAPK3 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3." } }, { "@type": "Question", "name": "Quels médicaments affectent la voie MAPK3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour MAPK3 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3." } }, { "@type": "Question", "name": "Comment la nutrition influence-t-elle MAPK3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "MAPK3 est-elle liée à des maladies auto-immunes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes." } }, { "@type": "Question", "name": "Comment MAPK3 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer." } }, { "@type": "Question", "name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires." } }, { "@type": "Question", "name": "MAPK3 peut-elle influencer le vieillissement ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à MAPK3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus." } }, { "@type": "Question", "name": "L'âge influence-t-il l'activité de MAPK3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il MAPK3 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques." } }, { "@type": "Question", "name": "Des infections peuvent-elles affecter MAPK3 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales peuvent perturber la signalisation de MAPK3." } } ] } ] }

Sources (10000 au total)

Medical Management of Headache and Facial Pain in CRS: A Systematic Review and Meta-Analysis.

This study aims to characterize the effect of medical therapy on headache and facial pain/pressure among patients with chronic rhinosinusitis (CRS).... CINAHL, PubMed, and Scopus.... CINAHL, PubMed, and Scopus were searched from inception through April 10th, 2024, for English language articles reporting headache or facial pain/pressure outcomes in CRS patients. Inclusion was restr... The initial search yielded 2429 unique articles. After a full-text review of 272 articles, 17 studies reporting outcomes for 2269 patients were included in the meta-analysis. The mean patient age was ... Our findings suggest medical therapy significantly reduces facial pain and pressure in the CRS population. Laryngoscope, 2024....

Incidence and Association of Uveitis with COVID-19 Vaccination: A Systematic Review and Meta-Analysis.

In the wake of the COVID-19 pandemic, vaccines have been pivotal in curbing disease spread and severity. However, concerns over post-vaccination adverse events, including uveitis, an inflammatory ocul... A literature search was performed across several databases on October 21, 2023. Human studies examining the incidence of uveitis post-COVID-19 vaccination were included. The Newcastle-Ottawa Scale was... Six studies involving over 2 billion vaccine doses were included. The overall incidence of uveitis was 0.016% (95% CI: 0.010 to 0.026). No significant association was found between vaccination and the... This analysis indicates a low incidence of uveitis following COVID-19 vaccination and no significant association with the vaccine. The findings are constrained by the small number of studies and low c...

Relaxation Therapy and Human Milk Feeding Outcomes: A Systematic Review and Meta-Analysis.

Human milk feeding is a key public health goal to optimize infant and maternal/parental health, but global lactation outcomes do not meet recommended duration and exclusivity. There are connections be... To appraise all available evidence on whether the provision of relaxation interventions to lactating individuals improves lactation and well-being.... Embase, MEDLINE, CINAHL, Allied and Complementary Medicine Database, Web of Science, and the Cochrane Library were searched on September 30, 2023, and topic experts were consulted.... Two independent reviewers screened for eligibility. Inclusion criteria were full-text, peer-reviewed publications with a randomized clinical trial design. Techniques that were entirely physical (eg, m... Two independent reviewers extracted data and assessed risk of bias with the Cochrane Risk of Bias 2 tool. Fixed-effects meta-analysis and Grading of Recommendations, Assessment, Development, and Evalu... Prespecified primary outcomes were human milk quantity, length and exclusivity of human milk feeding, milk macronutrients/cortisol, and infant growth and behavior.... A total of 16 studies were included with 1871 participants (pooled mean [SD] age for 1656 participants, 29.6 [6.1] years). Interventions were music, guided relaxation, mindfulness, and breathing exerc... Results of this systematic review and meta-analysis suggest that provision of relaxation was associated with an increase in human milk quantity and infant weight gain and a slight reduction in stress ...

The burden of health expenditure on household impoverishment in Ethiopia: a systematic review and meta-analysis.

Ethiopia, like many low-income countries, faces significant challenges in providing accessible and affordable healthcare to its population. Health expenditure is a critical factor in determining the q... This systematic review and meta-analysis used the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. PubMed, Cochrane Library, HINARI, Google Scholar and Ep... This systematic review and meta-analysis included a total of 12 studies with a sample size of 66344 participants. The pooled incidence of impoverishment, among households, attributed to health expendi... The pooled incidence of impoverishment of households attributed to their health expenditure in Ethiopia was higher than the incidence of impoverishment reported by the world health organization in 202...

Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis.

The impact of sarcopenia in oncology is increasingly recognized, yet little is known about its clinical implications in breast cancer. This systematic review and meta-analysis estimates the overall pr... We systematically searched primary original research published before June 2023 in four databases: the Cochrane Library via Wiley, CINAHL Plus with Full Text, Embase via Elsevier Excerpta Medica, and ... The systematic review included 17 studies with a total of 9863 patients; the meta-analysis included 12 of these studies. The mean prevalence of sarcopenia in breast cancer (stages I-III) was 32.5%. Th... Sarcopenia is not just a state of muscle mass loss, but an influencing factor on therapeutic effects and survival rates in oncology. It is thus necessary to recognize the risk of sarcopenia throughout...

Risk of dementia and Alzheimer's disease associated with antidiabetics: A Bayesian network meta-analysis.

Dementia risk is substantially elevated in patients with diabetes. However, evidence on dementia risk associated with various antidiabetic regimens is still limited. This study aims to comprehensively... Cochrane Central Register of Controlled Trials, Embase, MEDLINE (PubMed) and Scopus were searched from inception to March 2024 (PROSPERO CRD 42022365927). Observational studies investigating dementia ... A total of 1,565,245 patients from 16 studies were included. Dementia and AD risks were significantly lower with metformin and sodium glucose co-transporter-2 inhibitors (SGLT2i). Metformin displayed ... Metformin and SGLT2i demonstrated lower dementia risk than other antidiabetic classes. Patient-specific factors may affect this relationship and cautious interpretation is warranted as metformin is ty...